Q BioMed Inc (OTCQB: $QBIO) CEO Pens Management
Piece Featured in Life Science Leader
NEW
YORK - April 28, 2016 (Investorideas.com Newswire) Q BioMed Inc. (OTC: QBIO), a biotechnology
acceleration company reports the Company's CEO was featured in an article he
wrote on venture capital titled Accelerators Enter When VCs Fear To Tread:
Life Science Leader
magazine is an essential
business journal for life science executives who work for everything from
emerging biotechs to Big Pharmas. Their content is designed to inform readers
of industry best practices and motivate them to implement those practices in
their businesses.
Each
month, Life Science Leader features interviews with executives from the leading
pharma and biotech companies, including Pfizer, Merck, Daiichi Sankyo,
Genentech, Genzyme, Eli Lilly, and Janssen, as well as the FDA and more. This
exclusive thought leadership provides an in-depth look into industry trends and
hot topics that will impact the growth of the pharma and biopharma markets. As
the market is continually growing and innovating, these insights provide
readers with actionable information and strategies to implement when navigating
the evolving clinical, manufacturing, entrepreneurial, and regulatory
landscapes.
Corin
explains how times have changed for start-up biotechnology companies, though,
and the challenges have grown in magnitude. These days, the very same venture
capital firms that would hand out a few dollars in the early stages now are
idling their time, investing much bigger sums only after much more development
has occurred.
In
the article, Corin leverages his expertise at Q BioMed Inc., where he focuses
on acquiring licenses to innovative biomedical assets in the private company
space or academic setting.
"Our
team at Q Bio are dedicated to providing those developers with the strategic
resources, developmental support, and expansion capital to ensure they meet
their potential, with the ultimate goal of enabling them to provide products to
patients in need. Our mission is to license and acquire innovative life
sciences assets and accelerate their product development timelines to
commercialize their drug candidates and devices or bring them to the next level
in terms of valuation inflection and the attention of the larger Pharma players
or IPO them as stand-alone companies or just grow a revenue model
organically", states Corin.
Excerpt from the
article:
"Most
venture funds, for example, have become increasingly impatient to harvest
returns from their investments, many expecting an 'exit' within only 2-4 years.
This trend has been adverse for many biomedical technologies, since they
generally have a much longer gestation cycle than communications, electronics
or information technologies. In addition, many biomedical technologies require
regulatory approvals, which further increases development costs and lengthens
the investment cycle."
The
one thing that really has not changed is the amount of equity the venture
capitalists want when they finally do invest. For those who are only interested
in getting their idea into the marketplace, giving up 80 or 90% of their
company may be acceptable. Jonas Salk refused to patent his polio vaccine
because his focus was preventing that disease and not making billions for
himself. Handing off the headaches of running a business to people who studied
accounting and marketing rather than organic chemistry and electrical
engineering may be the solution for many researchers.
To read the entire
article, please follow this link
About Q BioMed Inc.
Q BioMed Inc. ”Q“ is a biomedical acceleration and
development company. We are focused on acquiring companies and biomedical
assets. Q is dedicated to providing these target companies and assets,
strategic resources, developmental support, and expansion capital to ensure
they meet their developmental potential enabling them to provide products to patients
in need.
Forward-Looking
Statements:
This
press release may contain “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements include, but are not limited to, any
statements relating to our growth strategy and product development programs and
any other statements that are not historical facts. Forward-looking statements
are based on management’s current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause actual results to
differ materially from those currently anticipated are: risks related to our
growth strategy; risks relating to the results of research and development
activities; our ability to obtain, perform under and maintain financing and
strategic agreements and relationships; uncertainties relating to preclinical
and clinical testing; our dependence on third-party suppliers; our ability to
attract, integrate, and retain key personnel; the early stage of products under
development; our need for substantial additional funds; government regulation;
patent and intellectual property matters; competition; as well as other risks
described in our SEC filings. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any forward looking
statements contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such statement is
based, except as required by law.
Contact:
Denis Corin
CEO
Q BioMed Inc.
1 888 357 2435
Sign up for the
free investor news and stock alerts:
This
news is published on the Investorideas.com Newswire - a global digital news
source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party
sourced news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investment involves risk and
possible loss of investment. This site is currently compensated for news
publication and distribution, social media and marketing, content creation and
more. Contact each company directly regarding content and press release
questions. Disclosure is posted for each compensated news release, content
published /created if required but otherwise the news was not compensated for
and was published for the sole interest of our readers and followers. More
disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure:
QBIO has retained investorideas.com for PR, media, news publication and social
media effective February 5th for three months: two thousand five hundred per
month.
Additional info regarding BC Residents and global Investors:
Effective September 15 2008 - all BC investors should review all OTC and Pink
sheet listed companies for adherence in new disclosure filings and filing
appropriate documents with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894. Global
investors must adhere to regulations of each country.
